Subscriber access provided by UNIV OF CALIFORNIA SAN DIEGO LIBRARIES
Article
A Structure-based Virtual Screening Protocol for in silico Identification of Potential Thyroid Disrupting Chemicals Targeting Transthyretin Jin Zhang, Afshan Begum, Kristoffer Brännström, Christin Grundström, Irina Iakovleva, Anders Olofsson, Astrid Elisabeth Sauer-Eriksson, and Patrik L. Andersson Environ. Sci. Technol., Just Accepted Manuscript • DOI: 10.1021/acs.est.6b02771 • Publication Date (Web): 26 Sep 2016 Downloaded from http://pubs.acs.org on September 28, 2016
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Environmental Science & Technology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 30
Environmental Science & Technology
1
A Structure-based Virtual Screening Protocol for in
2
silico Identification of Potential Thyroid Disrupting
3
Chemicals Targeting Transthyretin
4
Jin Zhang†, Afshan Begum†, Kristoffer Brännström‡, Christin Grundström†, Irina Iakovleva‡,
5
Anders Olofsson‡, A. Elisabeth Sauer-Eriksson†, Patrik L. Andersson†*
6
†Department of Chemistry, Umeå University, SE-901 87 Umeå, Sweden
7
‡Department of Medical Biochemistry and Biophysics, Umeå University, SE-901 87 Umeå,
8
Sweden
9
Corresponding Author
10
*Email:
[email protected]. Phone: +46-90-786-5266, Fax: +46-90-786-7655
11
ACS Paragon Plus Environment
1
Environmental Science & Technology
Page 2 of 30
12
ABSTRACT
13
Thyroid disruption by xenobiotics is associated with a broad spectrum of severe adverse
14
outcomes. One possible molecular target of thyroid hormone disrupting chemicals (THDCs) is
15
transthyretin (TTR), a thyroid hormone transporter in vertebrates. To better understand the
16
interactions between TTR and THDCs, we determined the crystallographic structures of human
17
TTR in complex with perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and
18
2,2',4,4'-tetrahydroxybenzophenone (BP2). The molecular interactions between the ligands and
19
TTR were further characterized using molecular dynamics simulations. A structure-based virtual
20
screening (VS) protocol was developed with the intention of providing an efficient tool for the
21
discovery of novel TTR-binders from the Tox21 inventory. Among the 192 predicted binders,
22
twelve representatives were selected and their TTR binding affinities were studied with
23
isothermal titration calorimetry, of which seven compounds had binding affinities between 0.26-
24
100 µM. To elucidate structural details in their binding to TTR, crystal structures were
25
determined of TTR in complex with four of the identified compounds including 2,6-dinitro-p-
26
cresol, bisphenol S, clonixin and triclopyr. The compounds were found to bind in the TTR
27
hormone binding sites as predicted. Our results show that the developed VS protocol is able to
28
successfully identify potential THDCs and we suggest that it can be used to propose THDCs for
29
future toxicological evaluations.
30
ACS Paragon Plus Environment
2
Page 3 of 30
Environmental Science & Technology
31
INTRODUCTION
32
Thyroid hormone disrupting chemicals (THDCs) are anthropogenic compounds that disrupt the
33
homeostasis of the thyroid hormone (TH) system1 and can induce disorders in physiological
34
processes, including macronutrient metabolism, energy balance, brain development, and
35
reproduction.2 Exposure to THDCs poses a significant threat to human health, especially during
36
fetal development. Prenatal hypothyroxinemia induced by THDCs can impair the development
37
of the embryonic brain and lead to neurologic deficits such as visuo-spatial processing
38
difficulties3 and reduced learning and memory.4
39
Transthyretin (TTR), a homotetrameric serum protein that transports L-thyroxine (T4),5 has
40
been suggested to be a possible molecular target of THDCs such as per and polyfluoroalkyl
41
substances (PFASs)6 and hydroxylated polychlorinated biphenyls (OH-PCBs).7 TTR is the
42
primary TH transporter in developing rodents,8 fish, birds, and amphibians9 and THDCs can
43
disrupt TH transport by competitively binding to the two identical thyroxine binding sites (TBSs)
44
situated at the dimeric interface of TTR.10,11 TTR can also mediate delivery of THDCs across the
45
placental and blood-brain barrier into the fetus and brain.12-14 Most TTR in human plasma resides
46
in the apo form and the concentration of tetrameric TTR in plasma (4-7 µM)15,16 is significantly
47
higher than that of T4 (0.112 µM)17. This means that low affinity TTR-binders can, without
48
competing with T4, bind to TTR and be transported to vital organs where they may subsequently
49
cause adverse health effects including developmental disorders.18,19 Inuit populations that are
50
chronically exposed to relatively high levels of TTR-binding contaminants showed normal T4
51
levels, but TTR-assisted accumulation of THDCs could potentially cause developmental
52
disorders.20-22 It is thus critical to understand the molecular interactions between THDCs and
53
TTR, and more importantly to identify and reduce the exposure to THDCs that target TTR.
ACS Paragon Plus Environment
3
Environmental Science & Technology
Page 4 of 30
54
Virtual screening (VS) using molecular docking is an efficient means to reduce costs and
55
animal testing by identifying the most hazardous compounds in risk assessment processes or
56
prioritizing the most promising candidates in drug discovery.23,24 The method has been used to
57
propose novel TTR amyloid inhibitors25 and to identify environmental pollutants targeting
58
estrogen receptor.26,27 Molecular docking can give insights into ligand-protein binding
59
conformations, and this was used to reveal interactions between PFASs and human liver fatty-
60
acid binding proteins.28 Such studies provide a better understanding of critical molecular
61
interactions between hazardous compounds and their targets.
62
Crystal structures of ligand-protein complexes are an essential component in the development
63
of VS protocols. Over 200 crystal structures of TTR have been reported in the Protein Data Bank
64
(PDB),29,30 but only a few of these are in complex with environmental pollutants or their
65
metabolites. These include TTR complexes with pentabromophenol31 and OH-PCBs.10 In
66
addition, we recently determined the crystal structure of TTR with the brominated flame
67
retardant tetrabromobisphenol A (TBBPA).32 Additional crystal structures of TTR complexes
68
with environmental pollutants with large chemical variation would improve the development of a
69
VS protocol for environmental pollutants and increase our understanding of their interactions
70
with TTR at the molecular level.
71
In this study, we determined the X-ray structures of human TTR in complex with three
72
emerging contaminants that were shown to bind to TTR: perfluorooctanoic acid (PFOA),
73
perfluorooctanesulfonic acid (PFOS), and 2,2’,4,4’-tetrahydroxybenzophenone (BP2).6,33 PFOA
74
and PFOS are commonly used as stain, water, and grease repellents in food packaging, carpets,
75
and textiles as well as in fire-fighting foams.34 BP2 is used as a UV absorber in personal care
76
products and plastic materials.35 Exposure to PFOS and PFOA is associated with hypothyroidism
ACS Paragon Plus Environment
4
Page 5 of 30
Environmental Science & Technology
77
and an increasing incidence of osteoporosis.36-38 BP2 might cause the development of
78
endometriosis.39 These ligands together with TBBPA cover a wide chemical variation of TTR
79
ligands. Their TTR binding activities in human plasma were measured with a previously
80
established plasma assay.32,40 The ligand-TTR interactions in the X-ray structures were further
81
studied by performing molecular dynamics (MD) simulations, and residues important for the
82
interactions were proposed by decomposition of ligand-binding free energies using the
83
Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) method. Based on the novel
84
X-ray structures and the molecular interaction information, a structure-based VS protocol was
85
developed to identify THDCs targeting TTR from the Tox21 inventory of 7,849 organic
86
compounds.41 Twelve representative industrial compounds were selected for in vitro studies
87
using isothermal titration calorimetry (ITC). Of these, four hits have been co-crystallized with
88
TTR to study their binding conformations.
89
MATERIALS AND METHODS
90
Crystallization of the TTR-THDC complexes. Human wild-type TTR was purified and
91
crystallized in complex with PFOA, PFOS, BP2 and with four confirmed hits (bisphenol S
92
(BPS), clonixin, 2,6-dinitro-p-cresol (DNPC), and triclopyr) following the procedures described
93
previously.42,43 The purified TTR was dialyzed against 10 mM Na-phosphate buffer with 100
94
mM KCl (pH 7.6) and concentrated to 5 mg/mL using an Amicon Ultra centrifugal filter device
95
(Millipore, 3 kDa molecular-weight cutoff) and co-crystallized at room temperature with a 5-
96
molar excess of the compounds using the vapor-diffusion hanging drop method. A drop
97
containing 3 µL protein solution was mixed with 3 µL precipitant and equilibrated against 1 mL
98
reservoir solution containing 1.3–1.6 M sodium citrate and 3.5% v/v glycerol at pH 5.5 in 24-
ACS Paragon Plus Environment
5
Environmental Science & Technology
99 100
Page 6 of 30
well Linbro plates. Crystals grew to dimensions of 0.2 × 0.2 × 0.3 mm3 after 5 days. The crystals were cryoprotected with 12% v/v glycerol.
101
Crystallographic data collection, integration, and structure determination. The X-ray
102
diffraction data of the complexes were collected at the European Synchrotron Radiation Facility
103
(Grenoble, France) on beamline ID29 or ID23-1 and in-house instruments (Table S1 and S2).
104
The structure of human TTR (PDB ID: 1F415) and X-ray data from 38.2–2.5 Å resolution were
105
used in molecular replacement searches with the program PHASER.44 The models were refined
106
against all of the diffraction data using PHENIX.45 At the end of structure refinement,
107
anisotropic B-factors were refined. Manual map inspection was performed with COOT.46 The
108
details of the refinement statistics are shown in Table S1 and S2. Molecular graphics were
109
produced using CCP4mg.47 Structure factors and coordinates of the TTR complexes have been
110
deposited with the Protein Data Bank (PDB ID: 5JID (PFOA), 5JIM (PFOS), 5JIQ (BP2), 5LAF
111
(DNPC), 5L4I (clonixin), 5LAJ (BPS) and 5L4M (triclopyr)).
112
Molecular dynamics simulations. The MD simulations were prepared based on the three
113
structures of TTR complexes with BP2, PFOA (sharing similar binding profiles with PFOS), and
114
TBBPA32. Each system was prepared following the procedures described in the supporting
115
information. The MD simulations of each prepared system were performed using Amber 1448
116
with the following steps: 1) each system was minimized with two-stage energy minimizations, 2)
117
each system was gradually heated to 310 K and then equilibrated under NPT conditions for 1 ns,
118
and 3) the 20 ns production MD was performed under NPT conditions using a Langevin
119
thermostat and Berendsen barostat. Details of the simulation are described in the supporting
120
information.
ACS Paragon Plus Environment
6
Page 7 of 30
Environmental Science & Technology
121
MM-GBSA free-energy decomposition. We calculated the binding free energies of BP2,
122
PFOA, and TBBPA to TTR using the MM-GBSA method in AmberTools 1548 based on the last
123
10 ns of the MD trajectory. The contributions of each residue in the TBS to the ligand binding
124
were determined by the pairwise decomposition method. The five residues that contributed the
125
most to the enthalpic binding free energy of each ligand were considered to be important for
126
ligand-TTR interactions (Table S3). The entropy contributions were neglected due to low
127
prediction accuracy.49 The procedures and parameters are described in the supporting
128
information.
129
Collection and preparation of the ligand dataset. Two ligand sets were used in the study –
130
the TTR benchmarking set and the Tox21 inventory.41 The TTR benchmarking set (Table S4)
131
contained 155 TTR-binders and 10,197 in silico generated decoys (inactives).50 The TTR-binders
132
were collected from the scientific literature using an activity cutoff of Ki or IC50 ≤ 100 µM as
133
suggested by the US EPA in the studies of THDCs51 and estrogen disruptors26,52 and used in the
134
Tox21Challenge in silico model-developing exercise (more explanations given in supporting
135
information).53 The benchmarking set was used in the development and evaluation of the VS
136
protocol. The Tox21 dataset contains 7,849 industrial compounds and pharmaceuticals.54 For
137
each compound in the two sets, a maximum of 32 low-energy conformations were generated by
138
considering all chiral atoms using the Schrödinger LigPrep module under the OPLS_2005 force
139
field,55 and their ionization and tautomeric states were determined at pH 7.0 ± 1.0.
140
Molecular docking. Molecular docking models were developed using the TTR complex
141
structures with BP2, PFOA, and TBBPA. The TBS situated at the BB’ interface was described
142
by a grid box centered on its co-ligand. The prepared compounds in the TTR benchmarking set
143
were docked into each structure using the Schrödinger Glide module under standard precision.56
ACS Paragon Plus Environment
7
Environmental Science & Technology
Page 8 of 30
144
For the docking results, we assessed their VS performance and enrichment. The VS
145
performance of each model was described with the area under curve (AUC) value of the receiver
146
operating characteristic (ROC) curves. The AUC value was used because it is insensitive to the
147
ratio of actives versus decoys in the benchmarking set.57 The enrichment was characterized by
148
two enrichment factors (EFs) that were evaluated at 10% and 20% of the ranked database,
149
referred as EF10% and EF20%, respectively. The AUC values and EFs are given in Table S5.
150
Ligand-TTR interaction analysis. Residues important for ligand-TTR interactions were
151
identified using the MM-GBSA binding free-energy decomposition. The W188 water molecule
152
in the TTR-TBBPA complex was also considered because it was suggested to be critical for
153
mediating hydrogen bonds (H-bonds) between TBBPA and Ser117.32 For each initial hit
154
identified by molecular docking, we counted the number of electrostatic interactions (H-bonds
155
and salt bridges) with polar residues (including W188) and hydrophobic interactions with non-
156
polar residues based on their docking poses. The number of interactions together with the
157
docking score was used to refine the initial hits and identify the bioactive compounds from the
158
Tox21 inventory. The refined hits and their interactions with TTR are shown in Table S6. The
159
known TTR-binders identified among the refined hits are given in Table S7.
160
Measuring compound binding activity in human plasma. Binding activity of BP2, PFOS,
161
and PFOA to TTR in the presence of human plasma was measured with a previously established
162
plasma assay.40 Details of experimental procedures are given in supporting information.
163
Isothermal Titration Calorimetry. The binding affinities of twelve selected potential TTR-
164
binders were measured using an Auto-iTC200 (MicroCal, Malvern, UK) at 25 °C. The chemical
165
information and properties of the twelve compounds are shown in Table S8. Stock solutions
166
were prepared in dimethyl sulfoxide (DMSO) and diluted with phosphate-buffered saline (PBS,
ACS Paragon Plus Environment
8
Page 9 of 30
Environmental Science & Technology
167
pH=7.4) to a final level of 5% DMSO immediately before the ITC experiments.40 Aliquots of
168
each compound were titrated into the TTR buffer solution (30 or 90 µM) to reach a 10-fold molar
169
excess. For the control experiment, the compounds were titrated into the cell with only buffer.
170
Raw data were collected, subtracted for compound heats of dilution, and processed using the
171
MicroCal Origin software. Calorimetric data (Table S9) were plotted and fitted using the
172
standard single-site binding model to yield the binding affinities (Kd), enthalpy changes, and
173
entropy changes.
174
RESULTS AND DISCUSSION
175
Crystal structures of the TTR-THDC complexes. We co-crystallized human wild-type TTR
176
in complex with PFOA, PFOS, and BP2 and determined their structures at 1.2–1.4 Å resolution
177
(Table S1). The structures showed that all three ligands bind at the deep end of the TBS (Figure
178
1). Compared with T4, the three ligands have the ability to bind deeper in the pocket due to their
179
smaller molecular size (Figure S1).
180
Of particular interest are the TTR complex structures with PFOA and PFOS. The structures
181
share three unique features. 1) The two ligands bind with their hydrophobic tail inside the pocket
182
and their hydrophilic acid groups are surface exposed (Figure S2), which is different from our
183
previous assumption.33 2) The hydrophobic tail bends at the second to last carbon atom of the
184
ligand to accommodate the volume between two Ser117 residues and to allow the acid groups to
185
form salt bridges with Lys15. 3) The bent hydrophobic tail forces the hydroxyl groups on Ser117
186
to rotate away from the ligands (Figure 1), which creates a more hydrophobic pocket that favors
187
the ligand-TTR interactions.
188
BP2 interacts with TTR similarly as luteolin in the deep end of the TBS (Figure S2).58 Two
189
hydroxyl groups form hydrogen bonds with Ser117 residues, and the carbonyl group interacts
ACS Paragon Plus Environment
9
Environmental Science & Technology
Page 10 of 30
190
with Thr119. Interactions between the aromatic ring of BP2 and TTR involve van der Waal
191
contacts with the side chain of Leu17.
192
MD simulations for ligand-TTR interaction studies. We investigated the molecular
193
interactions between TTR and THDCs by performing MD simulations on the TTR complex
194
structures with BP2, PFOA, and TBBPA.32 All three ligands remained bound in the TBS, and the
195
root-mean-squared-deviation (RMSD) of the protein and ligands was under 2 Å throughout the
196
simulations (Figure S3 and Figure S4).
197
The ligand-TTR binding free energies were calculated using the MM-GBSA method based on
198
the last 10 ns of the MD trajectory. The calculated energies of the ligands correlate well with
199
their previously measured potencies (Figure S5).6,33,59 The energies were further decomposed to
200
reveal five residues of significance for the ligand-TTR interactions in each of the three complex
201
structures (Table S3). Two types of ligand-TTR interactions were identified electrostatic
202
interactions with the polar residues B-Thr119, B-Ser117, B’-Ser117, B-Lys15, and B’-Lys15 and
203
hydrophobic interactions with the non-polar residues B-Leu110, B-Leu17, B’-Leu17, and B-
204
Ala108. The electrostatic interactions account for specific ligand-TTR recognition and a large
205
proportion of the binding free energies,60-62 whereas the hydrophobic interactions were less
206
significant for ligand binding. The results also revealed that the three ligands interact with the
207
residues deeper in the TBS, e.g. Ser117, whereas T4 interacts with residues at the opening of the
208
TBS, e.g. Glu54.63 Information on the molecular interactions with the identified residues (Table
209
S3) was used to better understand the ligand-TTR interaction and to refine potential TTR-binders
210
for better identifying of bioactive compounds.
211
Molecular docking model. The accuracy of the molecular docking using Glide was assessed
212
by comparing the docking conformations of BP2, PFOA, and TBBPA with their X-ray
ACS Paragon Plus Environment
10
Page 11 of 30
Environmental Science & Technology
213
structures.33 The RMSD values for the co-ligands were lower than 2 Å (Table S5), indicating that
214
the molecular docking was able to reproduce the actual binding conformation. The prepared
215
compounds in the benchmarking set were docked into each TTR complex, and the docking
216
results were compared in terms of AUC values and enrichment factors (Table S5). The TTR-
217
TBBPA structure showed the best results with AUC of 0.75 and good early enrichment (EF10%
218
= 3.76 and EF20% = 2.95), and 141 binders were identified among the 155 binders in the
219
benchmark set (Table S5). The docking models based on the TTR-PFOA and TTR-BP2
220
structures had lower performances in identifying TTR-binders, probably because TBBPA best
221
reflects the majority of the halogenated and hydroxylated aromatic compounds in the benchmark
222
set. However, the two structures provide useful information for molecular interaction studies,
223
and the TTR-PFOA structure reveals the correct binding orientations of PFASs in the TBS where
224
the acidic group was found to interact with Lys15 rather than Ser117.
225
The impact of water in the TBS of the TTR-TBBPA complex was studied by evaluating the
226
model performance of the structure with and without water molecules in the TBS. The structure
227
with water in the TBS outperformed the one without (Table S5 and Figure S6). After examining
228
the ligand-protein interactions in the TTR-TBBPA structure, the W188 water molecule was
229
found to be critical for mediating hydrogen bonds between the ligand and the Ser117 residues,
230
which agrees well with previously reported data.32
231
Binding activity of the studied THDCs to TTR in human plasma. We compared the
232
binding activity of BP2, PFOA, and PFOS to TTR in human plasma in terms of their inhibitory
233
concentrations at 50% (IC50) to prevent tetrameric dissociation in the established assay.32,40 BP2
234
bound strongly to TTR with an IC50 of 4 µM, while PFOA (IC50 = 175 µM) and PFOS (IC50 =
235
103 µM) had poor binding activity to TTR in plasma (Figure S7). Their differences in binding
ACS Paragon Plus Environment
11
Environmental Science & Technology
Page 12 of 30
236
activity could be caused by the hydrophobic tails of the PFASs giving limited electrostatic
237
contributions to their TTR binding, which are critical for molecular recognition.40,62 TBBPA has
238
also shown strong binding to TTR (IC50 = 3.3 µM).32 Clearly, BP2 share characteristics with
239
TBBPA in terms of molecular interactions with TTR. It is thus of interest to identify
240
contaminants sharing similar molecular interactions with TTR as found in BP2 and TBBPA.
241
Virtual screening of industrial compounds. The docking model developed using the TTR-
242
TBBPA structure was used as the basis for the VS of the Tox21 inventory because of its high VS
243
performance and the strong binding of TBBPA to TTR in human plasma. We applied a two-step
244
procedure to identify potential TTR-binders from the Tox21 inventory. In the first step,
245
compounds were docked into the TTR-TBBPA structure followed by ranking based on their
246
standard precision docking score. For each industrial compound, all protonation states in the
247
range of pH 7.0±1.0 were considered during the molecular docking. As suggested by previous
248
studies,64,65 we selected its top scored protonation form (Table S4 and S6), since docking score
249
considers both binding affinity and tautomeric ratio.66,67 The top 20% scored compounds
250
covering 1,282 hits were considered as initial hits for TTR, and these were extracted for further
251
analysis. In the second step, the initial hits were further refined by selecting those that showed at
252
least three electrostatic interactions with the identified polar residues (including W188), and two
253
hydrophobic interactions with the non-polar residues. The criteria were based on the interactions
254
between TTR and TBBPA that binds to TTR with a Kd of 20 nM.32 The electrostatic interactions
255
have been suggested to be critical for specific recognition of TTR.60-62 A total of 192 substances
256
among the top 20% scored compounds also fulfilled the molecular interaction criteria (Table S6)
257
and thus were predicted to be potential TTR binders by the VS protocol. Eleven known TTR-
258
binders were identified (Table S7), including five pharmaceuticals (including diflunisal and
ACS Paragon Plus Environment
12
Page 13 of 30
Environmental Science & Technology
259
aceclofenac),40 two flame retardants (TBBPA and tetrachlorobisphenol A), one herbicide (2,4,5-
260
trichlorophenoxyacetic acid (2,4,5-T)),33 one UV filter BP2, and one T4 derivative (3,3´,5,5´-
261
tetraiodothyroacetic acid).68 The recognition of these known TTR binders by the VS protocol
262
indicates that it is capable of identifying potential TTR-binders for further toxicological
263
investigations.
264
Binding affinities of selected compounds. We selected twelve representative compounds
265
(Table 1) for in vitro validation from the VS results based on their various applications, structural
266
diversity, and environmental relevance. These compounds mainly represent herbicides and
267
polymer additives (plasticizers and polymerization inhibitors) and include primarily halogenated
268
and/or aromatic substances as well as nitro compounds. The thermodynamic profiles of the
269
ligand-TTR binding were investigated using ITC (Figure 2). One TTR tetramer can bind two
270
ligands. However, we fitted ITC thermograms (Figure 2) using a one-site binding model as
271
binding of the first ligand dominates the total binding energy and its affinity is approximately
272
100 times stronger than the second ligand.69,70 The ITC results showed that seven of the twelve
273
compounds bound to TTR with Kd values below 100 µM (Table 1) indicating that our VS
274
protocol gave a reasonable hit rate of approximately 60%, which can be compared with
275
commonly practiced VS campaigns that generally have a hit rate of 20-40%.71,72 The
276
thermodynamic data (Table S9) revealed that the binding of BPS, clonixin, fluroxypyr,
277
mesotrione, and triclopyr was largely driven by the enthalpic component, whereas the binding
278
energy of DNPC and picloram was mainly entropy driven. The affinities of the active
279
compounds were not correlated with their docking scores (Figure S8), which was not surprising
280
since docking scores generally give poor estimations of the binding affinities.73,74 However, the
281
trend is correct (except DNPC), as more negative docking scores are associated with higher
ACS Paragon Plus Environment
13
Environmental Science & Technology
Page 14 of 30
282
affinities. Notably, five predicted binders showed no activities in the ITC experiments (Figure
283
S9) and we provide a thorough discussion on the potential reasons for their mispredictions in the
284
supporting information.
285
Crystal structures of the TTR-confirmed hits complexes. Four confirmed TTR-binders
286
(clonixin, DNPC, triclopyr and BPS) were selected for co-crystallization with human wild-type
287
TTR, considering their high binding affinities, diverse structures and various applications. The
288
crystal structures were determined at 1.5-1.6 Å resolution (Table S2). Compared with T4, the
289
four ligands bind deeper in the TBS due to their smaller molecular size (Figure 3). Clonixin
290
interacts with TTR similarly as flufenamic acid.75 It forms H-bonds and salt bridges with Lys15
291
(Figure S10). DNPC presents different binding conformations in the two TBSs. Furthermore, in
292
the AA’ interface, two DNPC molecules bind into the TBS simultaneously where one DNPC
293
interacts with Ser117 at the deep end of TBS, whereas the other DNPC binds to Lys15 at the
294
cavity entrance (Figure S10). In the BB’ interface, DNPC also binds in two different
295
orientations, however these conformations are different from the ones in AA’ and both cannot be
296
occupied at the same time as their binding sites overlap (Figure 3). The multiple conformations
297
of DNPC give better knowledge on interactions between TTR and nitro compounds, which
298
provides guidance for molecular design and risk assessment. Triclopyr interacts with TTR by
299
having electrostatic interactions with Lys15. BPS binds in the TBS similarly as TBBPA.32 Its
300
hydroxyl groups interact with Lys15 and form water-bridged H-bonds with Thr119 and Ser117
301
(Figure S8). We compared the docking pose of each ligand with its crystal conformation in the
302
BB’ interface (Figure S11) and the results showed that we correctly predicted the binding
303
conformations for clonixin, DNPC, and triclopyr. The inaccurate prediction of BPS may be due
304
to its weaker affinity and high mobility in the TBS. Besides DNPC, EMD21388 was also
ACS Paragon Plus Environment
14
Page 15 of 30
Environmental Science & Technology
305
reported to adapt to distinctive binding-modes in the two TBSs.76 Ensemble docking has been
306
proposed as a suitable strategy for predicting conformation of such ligands,77,78 which however
307
was not completed here due to lack of TTR structures with similar binding-modes to DNPC.
308
Environmental implications of the potential THDCs. Seven compounds with diverse
309
structures and various applications were identified as TTR-binders (Table 1). These compounds
310
warrant further toxicological investigations considering the following two reasons: (1) humans
311
may be chronically exposed to the compounds at doses that are similar or significantly higher
312
than normal T4 level (0.112 µM)17. In vivo levels of the compounds have been reported to be
313
35844 µM (9.416 mg/ml) for clonixin79, 0.312 µM (0.08 µg/ml) for triclopyr80, 3.72 µM (0.93
314
µg/ml) for BPS81, and 9.19 µM (2.22 µg/ml) for picloram82. (2) Low-affinity binders could be
315
effectively transported by TTR and accumulated in vulnerable organs in vivo,12-14 since most
316
TTR in human plasma resides in the apo form.15-17 Their accumulations could subsequently
317
induce adverse effects including developmental disorders.18,19
318
Interestingly, BPS, a replacement for bisphenol A (BPA), bound to TTR with a Kd of 52 µM.
319
BPS is used extensively as a plasticizer in BPA-free consumer products and as an anticorrosive
320
agent in canned food. Despite claims that it is a safer alternative to BPA, BPS has been reported
321
to pose similar potential health hazards as BPA in a number of in vitro and in vivo studies.83
322
Embryonic exposure to BPS is associated with neurogenesis within the hypothalamus, causing
323
gestation and hyperactivity in juvenile zebrafish84 and non-associative learning impairments in
324
adult zebrafish.85 BPS can also decrease plasma TH levels and impair the reproductive potential
325
of zebrafish.86 It was also found in dust samples in twelve countries, and the highest median
326
concentration was in Greece (860 ng/g).87
ACS Paragon Plus Environment
15
Environmental Science & Technology
Page 16 of 30
327
Clonixin was the strongest TTR binder identified in the Tox21 inventory and had a Kd of 0.26
328
µM. Clonixin is a non-steroidal anti-inflammatory drug, and it has a similar structure and TTR
329
binding affinity as meclofenamic acid.40 To our knowledge, its thyroid effects have not been
330
studied.
331
DNPC is used as an inhibitor of styrene polymerization and a dye intermediate, and this
332
molecule showed the second strongest interaction with TTR. DNPC is an uncoupler of oxidative
333
phosphorylation in humans, and it can cause acute hyperthermia, kidney and liver failure, and
334
cerebral edema.88 DNPC has a high potential for accumulation in biota and humans.88
335
The herbicides fluroxypyr, mesotrione, picloram, and triclopyr were identified as TTR-binders,
336
with triclopyr being the strongest binder. Triclopyr is used as an alternative to 2,4,5-T, and it has
337
been reported to cause thyroid-related neurotoxicity89 and developmental toxicity in rats.90 The
338
major metabolite of triclopyr is 3,5,6-trichloro-2-pyridinol,91 which is also a TTR-binder,33 and it
339
has been reported to disrupt the levels of T4 and thyroid stimulating hormone in humans.92
340
Exposure to triclopyr poses a significant threat to its applicators, and the amount in their urine
341
samples was reported to be 1–13 mg/day.93 The compound has been detected in water samples
342
from Australia,94 France,95 and multiple locations in the US.96,97 Environmental implications of
343
the other three herbicides are given in the supporting information.
344
In summary, we have determined the binding conformations of PFOS, PFOA, and BP2 in the
345
TBS of TTR. The structures of the complexes provide valuable information for improving our
346
understanding of the molecular interactions between TTR and emerging contaminants. PFOS and
347
PFOA were previously reported as strong TTR-binders, but our results indicate that they are
348
weak binders in plasma, whereas BP2 showed strong binding activity . BP2 is thus more likely to
349
be transported by TTR and accumulated in vulnerable organs. Based on the novel TTR complex
ACS Paragon Plus Environment
16
Page 17 of 30
Environmental Science & Technology
350
structures and the information on molecular interactions obtained from MD simulations, a VS
351
protocol was developed for the identification of potential THDCs targeting TTR from the Tox21
352
inventory. The protocol proposed 192 industrial compounds as potential binders to TTR. Among
353
the twelve compounds tested using in vitro experiments, we identified seven novel TTR-binders
354
including clonixin, DNPC, triclopyr, fluroxypyr, BPS, picloram, and mesotrione. Most of these
355
have been detected in the environment and have shown adverse thyroid-related effects in animal
356
models. We further co-crystallized TTR with PBS, clonixin, DNPC, and triclopyr and their
357
structures showed that the compounds bind in the TBS as predicted by the VS protocol. We
358
suggest further in vivo studies on these TTR-targeting compounds especially as they may
359
accumulate in vulnerable organs.
360
Supporting Information
361
Details of the X-ray structures, plasma assay, and VS performance; the identified potential TTR-
362
binders and the compounds tested using ITC; procedures and results of the MD simulations and
363
MM-GBSA calculations can be found in the supporting information. This information is
364
available free of charge via the Internet at http://pubs.acs.org/.
365
ACKNOWLEDGMENT
366
This study was financed by the MiSSE project through grants from the Swedish Research
367
Council for the Environment, Agricultural Sciences and Spatial Planning (Formas) (210-2012-
368
131) and by the Swedish Research Council (VR) (521-2011-6427). The MD simulations were
369
conducted using the High Performance Computing Center North.
370
ACS Paragon Plus Environment
17
Environmental Science & Technology
Page 18 of 30
371 372
REFERENCES
373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412
(1) Murk, A. J.; Rijntjes, E.; Blaauboer, B. J.; Clewell, R.; Crofton, K. M.; Dingemans, M. M.; Furlow, J. D.; Kavlock, R.; Kohrle, J.; Opitz, R.; Traas, T.; Visser, T. J.; Xia, M.; Gutleb, A. C., Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol. In Vitro 2013, 27, (4), 1320-46. (2) Crofton, K. M., Thyroid disrupting chemicals: mechanisms and mixtures. Int. J. Androl. 2008, 31, (2), 209-23. (3) Haddow, J. E.; Palomaki, G. E.; Allan, W. C.; Williams, J. R.; Knight, G. J.; Gagnon, J.; O'Heir, C. E.; Mitchell, M. L.; Hermos, R. J.; Waisbren, S. E.; Faix, J. D.; Klein, R. Z., Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N. Engl. J. Med. 1999, 341, (8), 549-55. (4) Gilbert, M. E.; Rovet, J.; Chen, Z.; Koibuchi, N., Developmental thyroid hormone disruption: prevalence, environmental contaminants and neurodevelopmental consequences. Neurotoxicology 2012, 33, (4), 842-52. (5) Hornberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-Eriksson, A. E., A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 2000, 302, (3), 649-69. (6) Weiss, J. M.; Andersson, P. L.; Lamoree, M. H.; Leonards, P. E.; van Leeuwen, S. P.; Hamers, T., Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin. Toxicol. Sci. 2009, 109, (2), 206-16. (7) Cheek, A. O.; Kow, K.; Chen, J.; McLachlan, J. A., Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. Environ. Health Perspect. 1999, 107, (4), 273-8. (8) Lans, M. C.; Spiertz, C.; Brouwer, A.; Koeman, J. H., Different competition of thyroxine binding to transthyretin and thyroxine-binding globulin by hydroxy-PCBs, PCDDs and PCDFs. Eur. J. Pharmacol. 1994, 270, (2-3), 129-36. (9) Schreiber, G., The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J. Endocrinol. 2002, 175, (1), 61-73. (10) Purkey, H. E.; Palaninathan, S. K.; Kent, K. C.; Smith, C.; Safe, S. H.; Sacchettini, J. C.; Kelly, J. W., Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem. Biol. 2004, 11, (12), 1719-28. (11) Eneqvist, T.; Lundberg, E.; Karlsson, A.; Huang, S.; Santos, C. R.; Power, D. M.; SauerEriksson, A. E., High resolution crystal structures of piscine transthyretin reveal different binding modes for triiodothyronine and thyroxine. J. Biol. Chem. 2004, 279, (25), 26411-6. (12) Kim, S. Y.; Choi, E. S.; Lee, H. J.; Moon, C.; Kim, E., Transthyretin as a new transporter of nanoparticles for receptor-mediated transcytosis in rat brain microvessels. Colloids Surf. B. Biointerfaces 2015, 136, 989-96. (13) Meerts, I. A.; Assink, Y.; Cenijn, P. H.; Van Den Berg, J. H.; Weijers, B. M.; Bergman, A.; Koeman, J. H.; Brouwer, A., Placental transfer of a hydroxylated polychlorinated biphenyl and effects on fetal and maternal thyroid hormone homeostasis in the rat. Toxicol. Sci. 2002, 68, (2), 361-71.
ACS Paragon Plus Environment
18
Page 19 of 30
413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458
Environmental Science & Technology
(14) Diamanti-Kandarakis, E.; Bourguignon, J. P.; Giudice, L. C.; Hauser, R.; Prins, G. S.; Soto, A. M.; Zoeller, R. T.; Gore, A. C., Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev. 2009, 30, (4), 293-342. (15) Ritchie, R. F.; Palomaki, G. E.; Neveux, L. M.; Navolotskaia, O.; Ledue, T. B.; Craig, W. Y., Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J. Clin. Lab. Anal. 1999, 13, (6), 273-9. (16) Ritchie, R. F.; Palomaki, G. E.; Neveux, L. M.; Navolotskaia, O., Reference distributions for the negative acute-phase proteins, albumin, transferrin, and transthyretin: a comparison of a large cohort to the world's literature. J. Clin. Lab. Anal. 1999, 13, (6), 280-6. (17) Hollowell, J. G.; Staehling, N. W.; Flanders, W. D.; Hannon, W. H.; Gunter, E. W.; Spencer, C. A.; Braverman, L. E., Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002, 87, (2), 489-99. (18) Boas, M.; Feldt-Rasmussen, U.; Main, K. M., Thyroid effects of endocrine disrupting chemicals. Mol. Cell. Endocrinol. 2012, 355, (2), 240-248. (19) Porterfield, S. P., Thyroidal dysfunction and environmental chemicals--potential impact on brain development. Environ. Health Perspect. 2000, 108 Suppl 3, 433-8. (20) Dallaire, R.; Muckle, G.; Dewailly, E.; Jacobson, S. W.; Jacobson, J. L.; Sandanger, T. M.; Sandau, C. D.; Ayotte, P., Thyroid hormone levels of pregnant inuit women and their infants exposed to environmental contaminants. Environ. Health Perspect. 2009, 117, (6), 1014-20. (21) Audet-Delage, Y.; Ouellet, N.; Dallaire, R.; Dewailly, E.; Ayotte, P., Persistent organic pollutants and transthyretin-bound thyroxin in plasma of Inuit women of childbearing age. Environ. Sci. Technol. 2013, 47, (22), 13086-92. (22) Plusquellec, P.; Muckle, G.; Dewailly, E.; Ayotte, P.; Begin, G.; Desrosiers, C.; Despres, C.; Saint-Amour, D.; Poitras, K., The relation of environmental contaminants exposure to behavioral indicators in Inuit preschoolers in Arctic Quebec. Neurotoxicology 2010, 31, (1), 17-25. (23) Rabinowitz, J. R.; Goldsmith, M. R.; Little, S. B.; Pasquinelli, M. A., Computational molecular modeling for evaluating the toxicity of environmental chemicals: prioritizing bioassay requirements. Environ. Health Perspect. 2008, 116, (5), 573-7. (24) Muralidharan, A. R.; Selvaraj, C.; Singh, S. K.; Sheu, J. R.; Thomas, P. A.; Geraldine, P., Structure-Based Virtual Screening and Biological Evaluation of a Calpain Inhibitor for Prevention of Selenite-Induced Cataractogenesis in an in Vitro System. J. Chem. Inf. Model. 2015, 55, (8), 1686-97. (25) Simoes, C. J.; Mukherjee, T.; Brito, R. M.; Jackson, R. M., Toward the discovery of functional transthyretin amyloid inhibitors: application of virtual screening methods. J. Chem. Inf. Model. 2010, 50, (10), 1806-20. (26) Rabinowitz, J. R.; Little, S. B.; Laws, S. C.; Goldsmith, M. R., Molecular modeling for screening environmental chemicals for estrogenicity: use of the toxicant-target approach. Chem. Res. Toxicol. 2009, 22, (9), 1594-602. (27) McRobb, F. M.; Kufareva, I.; Abagyan, R., In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor alpha. Toxicol. Sci. 2014, 141, (1), 188-97. (28) Zhang, L.; Ren, X. M.; Guo, L. H., Structure-based investigation on the interaction of perfluorinated compounds with human liver fatty acid binding protein. Environ. Sci. Technol. 2013, 47, (19), 11293-301.
ACS Paragon Plus Environment
19
Environmental Science & Technology
459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503
Page 20 of 30
(29) RCSB-PDB, RCSB Protein Data Bank (PDB). http://www.rcsb.org/pdb/ 2015. (30) Palaninathan, S. K., Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr. Med. Chem. 2012, 19, (15), 2324-42. (31) Ghosh, M.; Meerts, I. A.; Cook, A.; Bergman, A.; Brouwer, A.; Johnson, L. N., Structure of human transthyretin complexed with bromophenols: a new mode of binding. Acta Crystallogr. D Biol. Crystallogr. 2000, 56, (Pt 9), 1085-95. (32) Iakovleva, I.; Begum, A.; Brannstrom, K.; Wijsekera, A.; Nilsson, L.; Zhang, J.; Andersson, P. L.; Sauer-Eriksson, A. E.; Olofsson, A., Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer. PLoS One 2016, 11, (4), e0153529. (33) Zhang, J.; Kamstra, J. H.; Ghorbanzadeh, M.; Weiss, J. M.; Hamers, T.; Andersson, P. L., In Silico Approach To Identify Potential Thyroid Hormone Disruptors among Currently Known Dust Contaminants and Their Metabolites. Environ. Sci. Technol. 2015, 49, (16), 10099-107. (34) US-EPA Emerging Contaminants-Perfluorooctane Sulfonate (PFOS)and Perfluorooctanoic Acid (PFOA); The United States Environmental Protection Agency, 2014. (35) Spyropoulos, D. V., Stability testing of the plastics additives 2,4-dihydroxybenzophenone, 2,2 '-dihydroxy-4-methoxybenzophenone, 2-hydroxy-4-n-octyloxybenzophenone, 2-ethoxy-2ethyloxanilide (tinnvin 312) and 2,2 '-methylenebis(4-methyl-t-tert-butyl phenol) in aqueous and fatty food simulants. Food Addit. Contam. 1998, 15, (3), 362-369. (36) Melzer, D.; Rice, N.; Depledge, M. H.; Henley, W. E.; Galloway, T. S., Association between serum perfluorooctanoic acid (PFOA) and thyroid disease in the U.S. National Health and Nutrition Examination Survey. Environ. Health Perspect. 2010, 118, (5), 686-92. (37) Lopez-Espinosa, M. J.; Mondal, D.; Armstrong, B.; Bloom, M. S.; Fletcher, T., Thyroid function and perfluoroalkyl acids in children living near a chemical plant. Environ. Health Perspect. 2012, 120, (7), 1036-41. (38) Khalil, N.; Chen, A.; Lee, M.; Czerwinski, S. A.; Ebert, J. R.; DeWitt, J. C.; Kannan, K., Association of Perfluoroalkyl Substances, Bone Mineral Density, and Osteoporosis in the U.S. Population in NHANES 2009-2010. Environ. Health Perspect. 2016, 124, (1), 81-7. (39) Kunisue, T.; Chen, Z.; Buck Louis, G. M.; Sundaram, R.; Hediger, M. L.; Sun, L.; Kannan, K., Urinary concentrations of benzophenone-type UV filters in U.S. women and their association with endometriosis. Environ. Sci. Technol. 2012, 46, (8), 4624-32. (40) Iakovleva, I.; Brannstrom, K.; Nilsson, L.; Gharibyan, A. L.; Begum, A.; Anan, I.; Walfridsson, M.; Sauer-Eriksson, A. E.; Olofsson, A., Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma. J. Med. Chem. 2015, 58, (16), 6507-15. (41) US-NRC Toxicity Testing in the 21st Century: a Vision and a Strategy.; National Research Council. : National Academies Press. Washington, DC, 2007. (42) Johnson, S. M.; Connelly, S.; Wilson, I. A.; Kelly, J. W., Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J. Med. Chem. 2009, 52, (4), 1115-25. (43) Lindhagen-Persson, M.; Vestling, M.; Reixach, N.; Olofsson, A., Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. Amyloid 2008, 15, (4), 240-5. (44) McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J., Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40, (Pt 4), 658-674.
ACS Paragon Plus Environment
20
Page 21 of 30
504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547
Environmental Science & Technology
(45) Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H., PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66, (Pt 2), 213-21. (46) Emsley, P.; Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60, (Pt 12 Pt 1), 2126-32. (47) McNicholas, S.; Potterton, E.; Wilson, K. S.; Noble, M. E., Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr. D Biol. Crystallogr. 2011, 67, (Pt 4), 386-94. (48) Case, D. A.; Darden, T. A.; Gusarov, S.; Kovalenko, A.; Kollman, P. A., Amber 2015 (AmberTools15 and Amber14), University of California, San Francisco. 2015. (49) Hou, T.; Wang, J.; Li, Y.; Wang, W., Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J. Chem. Inf. Model. 2011, 51, (1), 69-82. (50) Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K., Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 2012, 55, (14), 6582-94. (51) Freitas, J.; Miller, N.; Mengeling, B. J.; Xia, M.; Huang, R.; Houck, K.; Rietjens, I. M.; Furlow, J. D.; Murk, A. J., Identification of thyroid hormone receptor active compounds using a quantitative high-throughput screening platform. Current chemical genomics and translational medicine 2014, 8, 36-46. (52) Browne, P.; Judson, R. S.; Casey, W. M.; Kleinstreuer, N. C.; Thomas, R. S., Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model. Environ. Sci. Technol. 2015, 49, (14), 8804-14. (53) Huang, R.; Xia, M.; Nguyen, D.-T.; Zhao, T.; Sakamuru, S.; Zhao, J.; Shahane, S. A.; Rossoshek, A.; Simeonov, A., Tox21Challenge to build predictive models of nuclear receptor and stress response pathways as mediated by exposure to environmental chemicals and drugs. Frontiers in Environmental Science 2016, 3. (54) Tice, R. R.; Austin, C. P.; Kavlock, R. J.; Bucher, J. R., Improving the human hazard characterization of chemicals: a Tox21 update. Environ. Health Perspect. 2013, 121, (7), 756-65. (55) Schrödinger LigPrep, version 3.4, Schrödinger, LLC, New York, NY., 2015. (56) Schrödinger Glide, version 6.7, Schrödinger, LLC, New York, NY., 2015. (57) Jain, A. N.; Nicholls, A., Recommendations for evaluation of computational methods. J. Comput. Aided Mol. Des. 2008, 22, (3-4), 133-9. (58) Iakovleva, I.; Begum, A.; Pokrzywa, M.; Walfridsson, M.; Sauer-Eriksson, A. E.; Olofsson, A., The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response. PLoS One 2015, 10, (5), e0128222. (59) Hamers, T.; Kamstra, J. H.; Sonneveld, E.; Murk, A. J.; Kester, M. H.; Andersson, P. L.; Legler, J.; Brouwer, A., In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. Toxicol. Sci. 2006, 92, (1), 157-73. (60) Trivella, D. B.; dos Reis, C. V.; Lima, L. M.; Foguel, D.; Polikarpov, I., Flavonoid interactions with human transthyretin: combined structural and thermodynamic analysis. J. Struct. Biol. 2012, 180, (1), 143-53.
ACS Paragon Plus Environment
21
Environmental Science & Technology
548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593
Page 22 of 30
(61) Yokoyama, T.; Kosaka, Y.; Mizuguchi, M., Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin. J. Med. Chem. 2014, 57, (21), 8928-35. (62) Alhamadsheh, M. M.; Connelly, S.; Cho, A.; Reixach, N.; Powers, E. T.; Pan, D. W.; Wilson, I. A.; Kelly, J. W.; Graef, I. A., Potent kinetic stabilizers that prevent transthyretinmediated cardiomyocyte proteotoxicity. Sci. Transl. Med. 2011, 3, (97), 97ra81. (63) Wojtczak, A.; Cody, V.; Luft, J. R.; Pangborn, W., Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution. Acta Crystallogr. D Biol. Crystallogr. 1996, 52, (Pt 4), 758-65. (64) Pospisil, P.; Ballmer, P.; Scapozza, L.; Folkers, G., Tautomerism in computer-aided drug design. J. Recept. Signal Transduct. 2003, 23, (4), 361-371. (65) Martin, Y. C., Let's not forget tautomers. J. Comput. Aided Mol. Des. 2009, 23, (10), 693704. (66) Shelley, J. C.; Cholleti, A.; Frye, L. L.; Greenwood, J. R.; Timlin, M. R.; Uchimaya, M., Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput. Aided Mol. Des. 2007, 21, (12), 681-91. (67) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S., Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, (7), 1739-1749. (68) Muziol, T.; Cody, V.; Luft, J. R.; Pangborn, W.; Wojtczak, A., Complex of rat transthyretin with tetraiodothyroacetic acid refined at 2.1 and 1.8 A resolution. Acta Biochim. Pol. 2001, 48, (4), 877-84. (69) Ferguson, R. N.; Edelhoch, H.; Saroff, H. A.; Robbins, J.; Cahnmann, H. J., Negative cooperativity in the binding of thyroxine to human serum prealbumin. Preparation of tritiumlabeled 8-anilino-1-naphthalenesulfonic acid. Biochemistry 1975, 14, (2), 282-9. (70) Cheng, S. Y.; Pages, R. A.; Saroff, H. A.; Edelhoch, H.; Robbins, J., Analysis of thyroid hormone binding to human serum prealbumin by 8-anilinonaphthalene-1-sulfonate fluorescence. Biochemistry 1977, 16, (16), 3707-13. (71) Schneider, G., Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 2010, 9, (4), 273-6. (72) Zhu, T.; Cao, S.; Su, P. C.; Patel, R.; Shah, D.; Chokshi, H. B.; Szukala, R.; Johnson, M. E.; Hevener, K. E., Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J. Med. Chem. 2013, 56, (17), 6560-72. (73) Park, M. S.; Dessal, A. L.; Smrcka, A. V.; Stern, H. A., Evaluating docking methods for prediction of binding affinities of small molecules to the G protein betagamma subunits. J. Chem. Inf. Model. 2009, 49, (2), 437-43. (74) Warren, G. L.; Andrews, C. W.; Capelli, A. M.; Clarke, B.; LaLonde, J.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S., A critical assessment of docking programs and scoring functions. J. Med. Chem. 2006, 49, (20), 5912-31. (75) Peterson, S. A.; Klabunde, T.; Lashuel, H. A.; Purkey, H.; Sacchettini, J. C.; Kelly, J. W., Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, (22), 12956-60. (76) Muziol, T.; Cody, V.; Wojtczak, A., Comparison of binding interactions of dibromoflavonoids with transthyretin. Acta Biochim. Pol. 2001, 48, (4), 885-92.
ACS Paragon Plus Environment
22
Page 23 of 30
594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639
Environmental Science & Technology
(77) Totrov, M.; Abagyan, R., Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr. Opin. Struct. Biol. 2008, 18, (2), 178-84. (78) Frimurer, T. M.; Peters, G. H.; Iversen, L. F.; Andersen, H. S.; Moller, N. P.; Olsen, O. H., Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities. Biophys. J. 2003, 84, (4), 2273-81. (79) Bica, A.; Farinha, A.; Blume, H.; Barbosa, C. M., Determination of clonixin in plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr. A 2000, 889, (1-2), 135-41. (80) Marin-Water-Agency, Vegetation Management Plan 2010. www.marinwater.org/DocumentCenter/ (accessed Aug 6,2016). (81) Liao, C.; Liu, F.; Alomirah, H.; Loi, V. D.; Mohd, M. A.; Moon, H. B.; Nakata, H.; Kannan, K., Bisphenol S in urine from the United States and seven Asian countries: occurrence and human exposures. Environ. Sci. Technol. 2012, 46, (12), 6860-6. (82) Hall, J. C.; Deschamps, R. J. A.; Krieg, K. K., Immunoassays for the Detection of 2,4-D and Picloram in River Water and Urine. J. Agric. Food Chem. 1989, 37, (4), 981-984. (83) Rochester, J. R.; Bolden, A. L., Bisphenol S and F: A Systematic Review and Comparison of the Hormonal Activity of Bisphenol A Substitutes. Environ. Health Perspect. 2015, 123, (7), 643-50. (84) Kinch, C. D.; Ibhazehiebo, K.; Jeong, J. H.; Habibi, H. R.; Kurrasch, D. M., Low-dose exposure to bisphenol A and replacement bisphenol S induces precocious hypothalamic neurogenesis in embryonic zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2015, 112, (5), 1475-80. (85) Mersha, M. D.; Patel, B. M.; Patel, D.; Richardson, B. N.; Dhillon, H. S., Effects of BPA and BPS exposure limited to early embryogenesis persist to impair non-associative learning in adults. Behav Brain Funct 2015, 11, 27. (86) Naderi, M.; Wong, M. Y.; Gholami, F., Developmental exposure of zebrafish (Danio rerio) to bisphenol-S impairs subsequent reproduction potential and hormonal balance in adults. Aquat. Toxicol. 2014, 148, 195-203. (87) Wang, W.; Abualnaja, K. O.; Asimakopoulos, A. G.; Covaci, A.; Gevao, B.; JohnsonRestrepo, B.; Kumosani, T. A.; Malarvannan, G.; Minh, T. B.; Moon, H. B.; Nakata, H.; Sinha, R. K.; Kannan, K., A comparative assessment of human exposure to tetrabromobisphenol A and eight bisphenols including bisphenol A via indoor dust ingestion in twelve countries. Environ. Int. 2015, 83, 183-91. (88) ATSDR Toxicological Profile for Dinitrocresols; USA Agency for Toxic Substances and Disease Registry (ATSDR), 1995. (89) Reddy, T. P.; Manczak, M.; Calkins, M. J.; Mao, P.; Reddy, A. P.; Shirendeb, U.; Park, B.; Reddy, P. H., Toxicity of neurons treated with herbicides and neuroprotection by mitochondriatargeted antioxidant SS31. Int. J. Environ. Res. Public Health 2011, 8, (1), 203-21. (90) Carney, E. W.; Billington, R.; Barlow, S. M., Developmental toxicity evaluation of triclopyr butoxyethyl ester and triclopyr triethylamine salt in the CD rat. Reprod. Toxicol. 2007, 23, (2), 165-74. (91) Schmidt, L.; Muller, J.; Goen, T., Simultaneous monitoring of seven phenolic metabolites of endocrine disrupting compounds (EDC) in human urine using gas chromatography with tandem mass spectrometry. Anal. Bioanal. Chem. 2013, 405, (6), 2019-29. (92) Fortenberry, G. Z.; Hu, H.; Turyk, M.; Barr, D. B.; Meeker, J. D., Association between urinary 3, 5, 6-trichloro-2-pyridinol, a metabolite of chlorpyrifos and chlorpyrifos-methyl, and serum T4 and TSH in NHANES 1999-2002. Sci. Total Environ. 2012, 424, 351-5.
ACS Paragon Plus Environment
23
Environmental Science & Technology
640 641 642 643 644 645 646 647 648 649 650 651 652 653 654
Page 24 of 30
(93) Gosselin, N. H.; Brunet, R. C.; Carrier, G.; Dosso, A., Worker exposures to triclopyr: risk assessment through measurements in urine samples. Ann. Occup. Hyg. 2005, 49, (5), 415-22. (94) Tran, A. T.; Hyne, R. V.; Doble, P., Determination of commonly used polar herbicides in agricultural drainage waters in Australia by HPLC. Chemosphere 2007, 67, (5), 944-53. (95) Botta, F.; Fauchon, N.; Blanchoud, H.; Chevreuil, M.; Guery, B., Phyt'Eaux Cites: application and validation of a programme to reduce surface water contamination with urban pesticides. Chemosphere 2012, 86, (2), 166-76. (96) Battaglin, W. A.; Rice, K. C.; Focazio, M. J.; Salmons, S.; Barry, R. X., The occurrence of glyphosate, atrazine, and other pesticides in vernal pools and adjacent streams in Washington, DC, Maryland, Iowa, and Wyoming, 2005-2006. Environ. Monit. Assess. 2009, 155, (1-4), 281307. (97) Tagert, M. L.; Massey, J. H.; Shaw, D. R., Water quality survey of Mississippi's Upper Pearl River. Sci. Total Environ. 2014, 481, 564-73. (98) Purkey, H. E.; Dorrell, M. I.; Kelly, J. W., Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. U. S. A. 2001, 98, (10), 5566-71.
655 656 657 658
ACS Paragon Plus Environment
24
Page 25 of 30
659 660 661
Environmental Science & Technology
Graphical abstract
662 663 664
ACS Paragon Plus Environment
25
Environmental Science & Technology
Page 26 of 30
665 666
Table 1. Studied compounds with abbreviations, chemical abstract services (CAS) registry
667
numbers, usage, and binding affinities (Kd) determined using isothermal titration calorimetry. Compounds
Abbreviations
CAS
Usage
Kd (µM)a
3,3',5,5'-tetraiodo-L-thyronine
T4
51-48-9
Positive Control
0.09b
2-nitro-5-(2-chloro-4Acifluorfen trifluoromethylphenoxy)benzoic acid
50594-66-6
Herbicide
ND
2,2'-dihydroxy-4,4'dimethoxybenzophenone
BP6
131-54-4
UV absorber
ND
4,4'-dihydroxydiphenyl sulfone
BPS
80-09-1
Plasticizer
52
2-(3-chloro-2methylanilino)pyridine-3carboxylic acid
Clonixin
17737-65-4
Pharmaceutic 0.26 al
2,6-dinitro-p-cresol
DNPC
609-93-8
Polymerizati on inhibitor
1.3
diphenolic acid
DPA
126-00-1
Plasticizer
ND
2-[(4-amino-3,5-dichloro-6fluoro-2-pyridinyl)oxy]acetic acid
Fluroxypyr
69377-81-7
Herbicide
45
L-γ-glutamyl-p-nitroanilide
GPNA
67953-08-6
Food additive
ND
2-[4-(methylsulfonyl)-2nitrobenzoyl]-1,3cyclohexanedione
Mesotrione
104206-82-8
Herbicide
99
3,5,6-trichloro-4-aminopicolinic Picloram acid
1918-02-1
Herbicide
63
1-(4-sulfophenyl)-3-carboxy-5pyrazolone
PyT
118-47-8
Dye
ND
3,5,6-trichloro-2pyridinyloxyacetic acid
Triclopyr
55335-06-3
Herbicide
4.6
ACS Paragon Plus Environment
26
Page 27 of 30
668 669 670
Environmental Science & Technology
a
ND refers to non-detected affinity. bThe binding affinity of T4 is only an approximate value due to its thermal instability and poor solubility in the isothermal titration calorimetry buffer. The approximated binding affinity is similar to the value of 84 nM reported previously.98
671 672
ACS Paragon Plus Environment
27
Environmental Science & Technology
Page 28 of 30
673
674 675
Figure 1. (A) The TTR monomers in the dimer structure are shown as ribbons and are labeled A
676
and B. The symmetry-related monomers are labeled A´ and B´. Locations of the thyroxine
677
binding sites (TBSs) are shown as gray surfaces. (B) Close-up view of the crystallographic
678
binding conformations of (a) BP2, (b) PFOA, and (c) PFOS in the TBS. The refined (2|Fo|−|Fc|)
679
electron density is shown in gray mesh at 1σ level, and the anomalous difference map showing
680
the position of the sulfur atoms in PFOS is shown in violet mesh at 3σ level. The water
681
molecules present around the ligands are shown as red spheres.
682
ACS Paragon Plus Environment
28
Page 29 of 30
Environmental Science & Technology
683
684 685
Figure 2. Structures of active compounds and thermograms of their binding to TTR as
686
determined by isothermal titration calorimetry. The abbreviations of the compounds are given in
687
Table 1.
688
ACS Paragon Plus Environment
29
Environmental Science & Technology
Page 30 of 30
689
690 691
Figure 3. Crystallographic binding conformations of the selected active compounds and T4 in
692
the thyroid-binding site of TTR; (a) clonixin, (b) DNPC (in the AA’ interface), (c) DNPC (in the
693
BB’ interface), (d) triclopyr, (e) T4 (PDB ID: 2ROX, for comparison), and (f) BPS. The refined
694
(2|Fo|−|Fc|) electron density is shown in gray mesh at 1σ level. The water molecules present
695
around the ligands are shown as red spheres. The electron density of the second ring of BPS was
696
poorly defined probably due to high mobility.
697
ACS Paragon Plus Environment
30